The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy

Blood Pressure

Volumn 11, Issue 1, 2002, Pages 53-55

  Mutlu, Haşim ^a   Özhan, Hakan ^a   Ökçün, Bariş ^a   Okuyan, Ertuǧrul ^a   Yiǧit, Zerrin ^a   Erbaş, Cennet ^a   Küçükoģlu, M Serdar ^a   Gültekin, Nazmi ^a   Üner, Sinan ^a   Erdine, Serap ^a   Güven, Özen ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Essential hypertension; Left ventricular hypertrophy; Valsartan

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; ECHOGRAPHY; HEMODYNAMICS; HYPERTENSION; MIDDLE AGED; PATHOLOGY; PHARMACOKINETICS; TREATMENT OUTCOME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; TETRAZOLES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME; VALINE;

EID: 18344379304     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370502753543963     Document Type: Article

References (19)

1. Hypertension, hypertrophy, heart failure
2. The national history of borderline isolated systolic hypertension
3. Early heart failure in the population. The study of men born 1913
4. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial
5. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload
6. Asymptomatic ventricular arrhytmias and mortality risk in subjects with left ventricular hypertrophy
7. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study
8. Drug-induced modification of vascular structure: Effects of antihypertensive drugs
9. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension
10. Disparate effects of antihypertensive drugs on large artery distensibility and compliance in hypertension
11. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy
12. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy
13. Left ventricular mass and the risk of stroke in an elderly cohort: The Framingham Heart Study
14. Do antihypertensive drugs differ in their ability to regress left ventricular hypertrophy?
15. Prevalence and natural history of electrocardiographic left ventricular hypertrophy
16. Left ventricular hypertrophy and geometric remodeling in hypertension: Stimuli, functional consequences and prognostic implications
17. Assessment of the prevalence of left ventricular hypertrophy in hypertension
18. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: Comparison of six antihypertensive agents: The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents
19. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine